Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment

European Heart Journal

Volumn 29, Issue 8, 2008, Pages 1001-1010

  Karjalainen, Pasi P ^a   Vikman, Saila ^b   Niemelä, Matti ^c   Porela, Pekka ^d   Ylitalo, Antti ^a   Vaittinen, Mari Anne ^e   Puurunen, Marja ^f   Airaksinen, Tuukka J ^c   Nyman, Kai ^g   Vahlberg, Tero ^h   Airaksinen, K E Juhani ^d  

^a SATAKUNTA CENTRAL HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e VAASA CENTRAL HOSPITAL   (Finland)

^f JORVI HOSPITAL   (Finland)

^g JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^h UNIVERSITY OF TURKU   (Finland)

Author keywords

Angioplasty; Anticoagulation; Bleeding; Complications; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; DEVICE; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; REVASCULARIZATION; RISK; STABLE ANGINA PECTORIS; STENT THROMBOSIS; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; BLOOD LOSS, SURGICAL; CORONARY DISEASE; CORONARY THROMBOSIS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC;

EID: 45349095265     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn099     Document Type: Article

References (33)

1. Popma JJ, Bittl JA. Coronary angiography and intravascular ultrasonography. In: Braunwald E, Zipes DP, Libby P, ed. Heart Disease: Textbook of Cardiovascular Medicine. 6th ed. Philadelphia: WB Saunders; 2001. p387-421.
2. Grossman W. Historical perspective and present practice of cardiac catheterisation. In: Baim D, ed. Grossman's Cardiac Catheterization, Angiography and Intervention. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. 1-8.
3. Ansell J, Hirsh BJ, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:204S-233S.
4. Spandorfer JM, Lynch S,Weitz HH, Fertel S, Merli GJ. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 1999;84:478-480.
5. Lev-Ran O, Kramer A, Gurevitch J, Shapira I, Mohr R. Low-molecular-weight heparin for prosthetic heart valves: treatment failure. Ann Thorac Surg 2000;69:264-265.
6. Karjalainen PP, Ylitalo A, Airaksinen KEJ. Titanium and nitride oxide coated stents and paclitaxel eluting stents for coronary revascularization in an unselected population. J Invasive Cardiol 2006;18:462-468.
7. Karjalainen PP, Porela P, Ylitalo A, Vikman S, Nyman K, Vaittinen M-A, Airaksinen TJ, Niemela M, Vahlberg T, Airaksinen KE. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007;28: 726-732.
8. Korkeila PJ, Saraste MK, Nyman KM, Koistinen J, Lund J, Airaksinen KEJ. Transesophageal echocardiography in the diagnosis of thrombosis associated with permanent transvenous pacemaker electrodes. Pacing Clin Electrophysiol 2006;29:1245-1250.
9. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA 2001;285:2864-2870.
10. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497.
11. Buehl A, Zoefel P. SPSS 11: Introduction in Modern Data Analysis. 8th ed. Munich, Germany: Addison-Wesley; 2002.
12. Helft G, Gilard M, Le Feuvre C, Zaman AG. Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation. Nat Clin Pract Cardiovasc Med 2006;3:673-680.
13. Spyropoulos AC, Turpie AG, Dunn AS, Spandorfer J, Douketis J, Jacobson A, Frost FJ. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 2006;4:1246-1252.
14. Kovacs MJ, Kearon C, Rodger M, Anderson DR, Turpie AGG, Bates SM, Desjardins L, Douketis J, Kahn SR, Solymoss S, Wells PS. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004;110:1658-1663.
15. Jaffer AK, Ahmed M, Brotman DJ, Bragg L, Seshadri N, Qadeer MA, Klein A. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. J Thromb Thrombolysis 2005;20: 11-16.
16. Spyropoulos AC, Turpie AG. Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation. Curr Opin Pulm Med 2005;11:373-379.
17. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004;164:1319-1326.
18. Spyropoulos AC, Bauersachs RM, Omran H, Cohen M. Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy. Curr Med Res Opin 2006;22:1109-1122.
19. Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, Jacobson A, Deykin D, Matchar D. Managing oral anticoagulant therapy. Chest 2001;119(Suppl. 1):22S-38S.
20. MacDonald LA, Meyers S, Bennett CL, Fintel D, Grosshans N, Syegco R, Davidson CJ. Post-cardiac catheterisation access site complications and low-molecular-weight heparin following cardiac catheterisation. J Invasive Cardiol 2003;15:60-62.
21. Chang RJ, Doherty TM, Goldberg SL. How does warfarin affect the activated coagulation time? Am Heart J 1998;136:477-479.
22. Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis 1998;5(Suppl. 1):19S-24S.
23. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(Suppl. 1):8S-21S.
24. White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ III, Califf RM. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the superior yield of the new strategy of enoxaparin, revascularization and glycoprotein IIb/IIIa inhibitors (SYNERGY) trial. Am Heart J 2006;152:1042- 1050.
25. Larson BJG, Zumberg MS, Kitchens CS. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk. Chest 2005;127:922-927.
26. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903- 1912.
27. El-Jack SS, Ruygrok PN, Webster MW, Stewart JT, Bass NM, Armstrong GP, Ormiston JA, Pornratanarangsi S. Effectiveness of manual pressure hemostasis following transfemoral coronary angiography in patients on therapeutic warfarin anticoagulation. Am J Cardiol 2006;97:485-488.
28. ten Berg JM, Kelder JC, Suttorp MJ, Mast EG, Bal E, Ernst S, Verheugt F, Thijs Plokker HW. Effect of coumarins started before coronary angioplasty on acute complications and long-term follow-up: a randomised trial. Circulation 2000;102:386-391.
29. Jessup DB, Coletti AT, Muhlestein JB, Barry WH, Shean FC, Whisenant BK. Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy. Catheter Cardiovasc Interv 2003;60:180-184.
30. Lee SW, Chen MZ, Chan HW, Lam L, Guo JX, Mao JM, Lam KK, Guo LJ, Li HY, Chan KK. No subacute thrombosis and femoral bleeding complications under full anticoagulation in 150 consecutive patients receiving non-heparin-coated intracoronary Palmaz-Shatz stents. Am Heart J 1996;132:1135-1146.
31. Dangas G, Mehran R, Kokolis S, Feldman D, Satler LF, Pichard AD, Kent KM, Lansky AJ, Stone GW, Leon MB. Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices. J Am Coll Cardiol 2001;38:638-641.
32. Exaire JE, Tcheng JE, Kereiakes DJ, Kleiman NS, Applegate RJ, Moliterno DJ. Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel. Catheter Cardiovasc Interv 2005;64:369-372.
33. Legrand V, Doneux P, Martinez C, Gach O, Bellekens M. Femoral access management: comparison between two different vascular closure devices after percutaneous coronary intervention. Acta Cardiol 2005;60:482-488.